Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05994794 · ClinicalTrials.gov registry record · NA
Role of a Dietary Supplement in Lowering SAH in Healthy Adults With Elevated Plasma SAH and Normal Homocysteine Levels
A NA study, sponsored by Standard Process.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT05994794 is a NA study that has completed, run by Standard Process. The registered enrollment target is 40 participants.
The verdict
NCT05994794, a NA study, has completed, sponsored by Standard Process.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
S-adenosylhomocysteine (SAH) is the end-product of methylation reactions in the body and the precursor to homocysteine. Elevated SAH in the blood is a reflection of the dysregulation of what is known as the S-adenosylmethionine (SAM) cycle and has been associated with poor health outcomes. The SAM cycle is a series of reversible reactions necessary for the regulation of many processes in the body. The goal of this clinical trial is to assess the ability of a dietary supplement to support healthy plasma SAH levels in individuals with high plasma SAH. Participants in the study will attend a total of 4 clinic visits and consume study product daily for 12 weeks.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Alpha-GPC, Creatine and Ashwagandha (Sensoril®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-12-09 |
| Est. Completion | 2023-10-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05994794
The ClinicalTrials.gov registry entry for NCT05994794 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Standard Process, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05994794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05994794 about?
NCT05994794 is a clinical study titled "Role of a Dietary Supplement in Lowering SAH in Healthy Adults With Elevated Plasma SAH and Normal Homocysteine Levels". S-adenosylhomocysteine (SAH) is the end-product of methylation reactions in the body and the precursor to homocysteine. Elevated SAH in the blood is a reflection of the dysregulation of what is known as the S-adenosylmethionine (SAM) cycle and has been associated with poor health outcomes. The SAM c...
What is the current status of trial NCT05994794?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2022-12-09. Estimated completion is 2023-10-05.
What interventions are being tested in trial NCT05994794?
The interventions under investigation include: Placebo (OTHER), Alpha-GPC, Creatine and Ashwagandha (Sensoril®) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05994794?
This trial is sponsored by Standard Process, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.